Abstract
Immunosuppressive agents have a well-established role in the treatment of pruritus. However, a shift within this realm of antipruritic therapy is underway. While agents that reduce itch secondary to generalized immunosuppression have well-documented antipruritic effects, novel biologic agents are emerging with the ability to target itch-inducing immunologic cascades in a more specific manner. In addition, janus kinase (JAK) inhibitors and phosphodiesterase 4 (PDE4) antagonists are also demonstrating antipruritic capabilities. The arrival of these agents is expected to usher in a new era of immunomodulatory antipruritic therapy.